This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of an off-the-shelf, in situ chimeric antigen receptor regulatory T cell (CAR-Treg) therapy for transplant rejection. Optimeos Life Sciences, Inc., a biotechnology company, will use the funding to advance their nanoparticle-mediated delivery platform for targeted delivery of mRNA constructs encoding the CAR and FOXP3 to CD4+ T cells. The goal is to generate CAR-Treg cells in vivo, overcoming the challenges of complex ex vivo manufacturing processes associated with current CAR-Treg therapies. Over the two-year project period, Optimeos will select the lead nanoparticle formulation for targeted CD4+ T cell delivery and validate the mRNA constructs for CAR-Treg generation, with plans to demonstrate efficacy in a skin transplant model in a future Phase II study.
Generated 4/1/25, 4:07 AM